Jump to content

sjgpharma

Member
  • Posts

    6
  • Joined

  • Last visited

About sjgpharma

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

sjgpharma's Achievements

0

Reputation

  1. Here you have it lol. It is used for the treatment of obesity and related conditions, especially when used in conjunction with a synergistic compound AICAR , as the combination has been shown to significantly increase exercise endurance in human. Have you heard of S23, LGD-3033, SR9011, ACP-105 and AC-262536? There are some SARMs even unknown by the vet.
  2. What Is GW0742? GW0742 is a selective PPARδ agonist (EC50 = 1.1 nM) that exhibits 1,000-fold selectivity over the other human PPAR subtypes. GW0742 exhibits time-dependent neuroprotection in low KCl-induced apoptosis in cerebellar granule neuronal cultures. Despite the neuroprotective properties observed, prolonged (48h) incubation with GW0742 produced significant inherent toxicity. This cell death was determined to be apoptotic as identified with the TUNEL assay. Solubility Chloroform (Slightly), Methanol (Slightly)
  3. sjgpharma

    ACP-105 (NEW)

    What Is ACP-105? ACP-105 is another non-steroidal Selective Androgen Receptor Modulator (SARM). It is as potent as Testosterone in in vitro assays without interaction at other hormone receptors. In addition, ACP-105 demonstrates potent anabolic effects on muscle and bone with minimal effect on prostate in preclinical models. How Suppressive Is ACP-105? ACP-105 is a partial agonist; meanwhile LGD-4033 is a full agonist (using this comparison as LGD-4033 has a lot of supporting data to compare to). Full agonists induce greater levels of suppression, but are more potent (based on the information presented). With ACP-105 in particular, being a partial agonist it would result in less suppression, although it will also likely be weaker than LGD-4033 on a mg:mg comparison. Raising the dose could make it formidable to heavy hitters like LGD-4033, but referring back to the anabolic:androgenic rating of ACP-105 (3.19:1), we can assume that the higher the dose, the greater the chance of suppression and androgenic side effects. This may still be minimal though, even at higher dosages, as ACP-105 appears to have a much less significant effect on prostate size than Testosterone and DHT. Dosage The studies done on ACP-105 suggest that the human equivalent for the study using 1 mg/kg per day for a man weighing about 175 pounds would be about 11 mg per day. Obviously equating this to some efficacious dosage where there would be minimal/no side effects for human use is impossible to do without some sort of experimentation being done, and as of now there are no clinical trials done on humans. The consensus seems to suggest that a reasonable starting dosage is around 11-12mg per day for human research trials.
  4. sjgpharma

    Hello ?

    Happy to have you on board, welcome!
×
×
  • Create New...

Important Information

Guidelines